



27 February 2020

Sydney, Australia

Nyrada Inc. Corporate Presentation February 2020

Nyrada Inc. (ASX: NYR) is pleased to provide shareholders and the market the attached corporate presentation, "Kalkine Invest Nest Presentation February 2020".

This document will be used at the Kalkine Invest Nest 2020 Small Cap Investor Conference today.

The presentation will be available on the Nyrada Inc. website: www.nyrada.com.

About Nyrada Inc

Nyrada is a pre-clinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

www.nyrada.com

Approval. This announcement has been approved and authorised for release by Dr Graham Kelly, Nyrada Inc Non-Executive Director, by authority of the Nyrada Inc Board.

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0100
E: cstrong@citadelmagnus.com

Forward Looking Statements



This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.




(ASX : NYR)

Improving Lives, Offering Hope

*Developing New Therapies for
Cardiovascular and Neurological
Disorders*

James Bonnar
Chief Executive Officer

KALKINE Invest-Nest February 2020



Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

What is Nyrada?

**Newly Listed
Biotechnology
Company**

16 January 2020



**Initial Public
Offering (IPO)**

\$8.5 Million

**Australian
Securities
Exchange (ASX)**

NYR



Mission & Business Model

Innovative Treatments


Clinical Need

Market Potential

Commercial focus

Discovery/early phase

Diverse pipeline




Cardiovascular



Neurology




Cholesterol Problem



1 in 3 Deaths
attributed to
Cardiovascular
Disease

Cholesterol Problem (US)

Total of **62.6 million** US Adults with elevated LDL-C



27.4 million with elevated LDL-C take a statin

19.4 million unable to achieve LDL-C target despite taking statin therapy

Current Treatment Options



Low cost



Suboptimal efficacy
Side effects



Effective, combined with statin



Expensive
Inconvenient

Global sales statins approx. US\$19 billion

New Treatment Option



- ❑ Launch in March 2020
- ❑ US\$3,600 per year


⊖ Developed for use with a statin
Modest LDL-C reduction over statin alone

Nyrada Cholesterol-Lowering Solution

Blocks action of PCSK9
on cholesterol receptor


Statins increase
PCSK9 levels

High PCSK9 = high LDL
cholesterol



Small molecule PCSK9 inhibitor

What is Unique?



Cholesterol Drug Market (Non-Statin)

Injectable

Evolocumab (Repatha)	Marketed	Amgen	PCSK9 inhibitor	Monoclonal
Alirocumab (Praluent)	Marketed	Sanofi/Regeneron	PCSK9 inhibitor	Monoclonal
Inclisiran	Phase III	The Medicines Company / Novartis	PCSK9 siRNA	siRNA
Evinacumab	Phase III	Regeneron	ANGPTL3 inhibitor	Monoclonal
LY3015014	Phase II	Lilly	PCSK9 inhibitor	Monoclonal
AFFITOPE (AT04A)	Phase I	AFFiRiS AG	PCSK9	Vaccine

Oral

Bempedoic acid (Nexletol)	Marketed	Esperion	ATP citrate lyase inhibitor	Small molecule
P-21	Preclinical	Shifa Biomedical	PCSK9 inhibitor	Small molecule
NYX-330	Preclinical	Nyrada Inc.	PCSK9 inhibitor	Small molecule


Very little new competition for a new oral medication



Brain Injury Problem

Each year in the US:

- 2.8 million people suffer a traumatic brain injury
- 800,000 suffer a stroke



Nyrada Brain Injury Solution

- ❑ Treatment to prevent secondary brain injury
- ❑ Inhibitor of Ca^{2+} induced excitotoxicity

Intravenous or intranasal for 3-5 days post-injury

- ❑ Concussion & severe head trauma
- ❑ Stroke

Brain Injury Drug Market (US)

Traumatic Brain Injury (Moderate to Severe)

Hospital admissions per year	280k
Patients who present within 12-hour window (>75%)	210k


Stroke

Emergency room visits per year	650k
Patients who present within 12-hour window (>75%)	490k

Annual US market for brain injury combined:
approx. **700k** patients



Program Status



Board of Directors

Nyrada operates under the direction of a board of international calibre
Track record in founding and realising the value of biotech companies



**Mr John
Moore**
Non-
Executive
Chairman



**Dr Graham
Kelly**
Non-
Executive
Director



**Christopher
Cox**
Non-
Executive
Director



**Mr Peter
Marks**
Non-
Executive
Director



**Mr Marcus
Frampton**
Non-
Executive
Director



**Dr Rüdiger
Weseloh**
Non-
Executive
Director



Scientific Advisory Board

International team of experts with vast experience in drug development



**Prof Gary
Housley**
MSc PhD



**Prof Junichi
Nabekura**
PhD



**Prof David
Burke**
MD DSc AC




**Prof Gilles
Lambert**
PhD



Jim Palmer
PhD





- ✓ Large, under-served therapeutic areas
- ✓ Compelling proof of concept data
- ✓ Right team to execute


Discover More & Follow Us



Neuroprotection Animation



Cholesterol-Lowering Animation



Recent PCSK9i Publication

 @nyrada_inc

LinkedIn  @nyrada_inc

www.nyrada.com

